Pharmaceutical

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Disease): Likelihood of Approval

UI-059 is under clinical development by Korea United Pharm and currently in Phase I for Reflux Esophagitis (Gastroesophageal Reflux Disease).

Dec 20, 2023 - 18:00
UI-059 is under clinical development by Korea United Pharm and currently in Phase I for Reflux Esophagitis (Gastroesophageal Reflux Disease).
Read the original article

Tags:

Previous Article

GLB-001 by GluBio Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

Next Article

GUB-014295 by Gubra for Obesity: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Nostrum Labs and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates

STAT+: Nostrum Labs and its CEO — who once defended Shk...

Nov 1, 2023

STAT+: Pharmalittle: Patients brace for insurance decisions on weight loss drugs; Indian authorities find multiple problems at pharma plants

STAT+: Pharmalittle: Patients brace for insurance decis...

Aug 3, 2023

Nuvectis Pharma receives IND approval from FDA for NXP900

Nuvectis Pharma receives IND approval from FDA for NXP900

May 16, 2023